Literature DB >> 22553679

Detection and comparison of matrix metalloproteinase in primary and recurrent pterygium fibroblasts.

Mei-Xia An1, Kai-Li Wu, Shao-Chun Lin.   

Abstract

AIM: To detect and compare the levels of matrix metalloproteinases (MMPs) secreted by primary and recurrent human pterygium fibroblasts (HPFs).
METHODS: Primary and recurrent HPFs as well as human conjunctival fibroblasts (HCF) were cultured in RPMI 1640 medium at the same conditions. The protein levels of MMP-1, MMP-3 and MMP-9 were determined by enzyme-linked immune sorbent assay (ELISA), respectively.
RESULTS: 1) The protein level of MMP-1 in serum-free supernatant from cultured primary and recurrent HPFs was higher than that in normal HCFs (P<0.05); similarly, the protein level of MMP-1 in serum-free supernatant from cultured primary HPFs was higher than that in recurrent HCFs (P<0.05). 2) The protein level of MMP-3 in serum-free supernatant from cultured primary HPFs was higher than that in normal HCFs (P<0.05); meanwhile, the protein level of MMP-3 in serum-free supernatant from cultured recurrent HPFs was lower when compared with that in primary HPFs and normal HCFs (P<0.05). 3) MMP-9 was not detected in primary and recurrent HPFs in the conditioned medium.
CONCLUSION: The protein levels of MMP-1 and MMP-3 in supernatant secreted by primary HPFs are different from recurrent HPFs. Different pathological mechanisms may exist between primary and recurrent pterygia.

Entities:  

Keywords:  matrix metalloproteinase; primary and recurrent pterygia

Year:  2011        PMID: 22553679      PMCID: PMC3340879          DOI: 10.3980/j.issn.2222-3959.2011.04.05

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  5 in total

1.  Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head.

Authors:  N Di Girolamo; D Wakefield; M T Coroneo
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells.

Authors:  Nick Di Girolamo; Rakesh K Kumar; Minas T Coroneo; Denis Wakefield
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

3.  Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines.

Authors:  A Solomon; D Q Li; S B Lee; S C Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

4.  Matrix metalloproteinase-9 expression in pterygium.

Authors:  Silvana Artioli Schellini; Erika Hoyama; Deilson Elgui Oliveira; Carlos Eduardo Bacchi; Carlos Roberto Padovani
Journal:  Arq Bras Oftalmol       Date:  2006-05-08       Impact factor: 0.872

5.  Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells.

Authors:  N Dushku; M K John; G S Schultz; T W Reid
Journal:  Arch Ophthalmol       Date:  2001-05
  5 in total
  4 in total

Review 1.  Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis.

Authors:  Qing-Yang Feng; Zi-Xuan Hu; Xi-Ling Song; Hong-Wei Pan
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

2.  Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.

Authors:  Yeoun-Hee Kim; Jae-Chang Jung; Sang Il Gum; Su-Bin Park; Jin Yeul Ma; Yong Il Kim; Kyoo Won Lee; Young Jeung Park
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

Review 3.  Recurrent Pterygium: A Review.

Authors:  Leila Ghiasian; Bijan Samavat; Yasaman Hadi; Mona Arbab; Navid Abolfathzadeh
Journal:  J Curr Ophthalmol       Date:  2022-01-06

4.  DNA damage in human pterygium: one-shot multiple targets.

Authors:  Anca Maria Cimpean; Mihai Poenaru Sava; Marius Raica
Journal:  Mol Vis       Date:  2013-02-07       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.